Skip to Main Content

Paper Details

TRK xDFG Mutations Trigger a Sensitivity Switch from Type I to II Kinase Inhibitors.
Cancer Discov
30
2021
TRK, TRK fusion-positive cancers, TRKAG667, TRKCG696, oncogene, patients, tumors, type I TRK, type II TRK, xDFG-mutant isogenic and patient-derived models
Author NameAffiliation
Ji Eun LeeMemorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Michael F BergerCenter for Molecular Oncology, Memorial Sloan Kettering Cancer Center
Michael F BergerMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Barry S TaylorMemorial Sloan Kettering Cancer Center
Elisa de StanchinaMemorial Sloan Kettering Cancer Center
Alexander DrilonMemorial Sloan Kettering Cancer Center
Alexander DrilonWeill Cornell Medical College
  • 1 - 9

Datasets

Release 1.2